For decades, infants under about 4.5 kilograms were effectively excluded from malaria treatment. That gap has finally been filled with the approval of Coartem Baby, a sweet, dissolvable tablet made specifically for newborns and very young infants. The news, first reported by the Associated Press, has been described by health workers as nothing short of a breakthrough.
Why babies were left out
Malaria remains one of the most devastating diseases in sub-Saharan Africa, claiming nearly 600,000 lives each year, and more than three-quarters of those deaths are in children under five. Until now, no medicine had been licensed for newborns weighing between two and five kilograms. Doctors were forced to crush existing tablets and guess at appropriate dosages, a method that was both unreliable and risky.
Coartem Baby changes that. It is a carefully measured, flavoured tablet version of artemether-lumefantrine, one of the world’s most widely used antimalarial drugs. The formula has been adapted for the specific metabolism of infants, who process medicines differently from older children. For health workers, the difference between guessing and having a tailored treatment is profound — and could mean tens of thousands of lives saved every year.
How the new drug was developed
The medicine was created through a partnership between Novartis and Medicines for Malaria Venture, with support from international regulators who recognised the urgent need. According to a Novartis press release, the company plans to supply Coartem Baby on a not-for-profit basis to ensure it is affordable in countries where malaria is most deadly. Swissmedic, Switzerland’s medical regulator, was the first to authorise it, and that approval is now being recognised in several African nations including Uganda, Kenya, and Tanzania.
Getting to this stage required a new way of thinking about clinical trials. Infants are often excluded from drug research because of safety concerns, but in this case, scientists designed studies around their unique physiology, ensuring careful testing before rollout. It’s a shift that advocates hope will inspire more innovation targeted directly at children who have historically been sidelined in global health research.
What happens next
In Uganda, where malaria remains the leading cause of death for children under five, health officials are preparing to introduce the new drug in public hospitals and rural clinics. Training is already under way to help staff recognise malaria symptoms in newborns, which are often mistaken for sepsis. With a medicine finally designed for these babies, early diagnosis could lead to rapid treatment instead of fatal delay.
Health workers interviewed by the Associated Press described the medicine as a “game-changer.” Beyond the obvious lifesaving potential, the drug is also simple to administer: the tablet dissolves in water, tastes pleasant enough for babies to swallow, and provides reliable dosing without the guesswork. For parents, that reliability is huge. For clinics already stretched thin, it reduces stress and uncertainty.
The arrival of Coartem Baby comes at the same time as progress on vaccines. The RTS,S malaria vaccine is already being rolled out in several African countries, and a newer vaccine known as R21/Matrix-M is expected to expand access even further. Together, vaccines and infant-friendly treatment could dramatically reduce malaria’s toll on children.
But treatment and prevention need sustained funding. The World Health Organization has warned that global malaria programmes are under strain from reduced financing and climate change, which is altering mosquito patterns. Without political will and investment, even the best medicines can’t reach those who need them. That’s why the approval of this drug is being hailed not just as a medical advance, but as a call to action.
Why this matters globally
Although malaria is most closely associated with sub-Saharan Africa, it remains a global issue, with cases reported in Asia, Latin America, and even occasional outbreaks in Europe and the United States. The approval of a treatment designed for newborns shows what’s possible when the international community focuses on those at greatest risk.
For families who have lived with the daily fear of malaria, the symbolism matters as much as the science. A dissolvable tablet tailored to the smallest babies sends a powerful message: their lives count, and solutions can be made with them in mind. It’s also a template for other diseases where infants are left behind, from tuberculosis to HIV.
For now, the task is to get Coartem Baby into as many hands as possible, as quickly as possible. If governments, donors, and pharmaceutical companies follow through, the drug could help transform the outlook for millions of children born into malaria-endemic regions every year.
Malaria has long been called one of the oldest and deadliest killers. With innovations like this one, that description might finally start to change.